Moderna-Merck mRNA melanoma vaccine cuts relapse risk 42% in trial
A personalised mRNA vaccine from Moderna and Merck cut the risk of melanoma relapse or death by 42% in the Interpath-001 phase 3 trial of 1,137 patients.
Merck
1 story
1 story
A personalised mRNA vaccine from Moderna and Merck cut the risk of melanoma relapse or death by 42% in the Interpath-001 phase 3 trial of 1,137 patients.